Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$567.14M
EPS-1.3500
P/E Ratio-2.33
Earnings Date08/06/2026

prme

Shares Outstanding

Last Annual Value

148.76M

3-Year CAGR

15%

5-Year CAGR

9%

10-Year CAGR

5%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of shares-outstanding

PRME · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
148.76M
17.8%9.2%N/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
133.94M
29.5%33.2%N/A
87.68M
6.2%5.7%16.7%
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
44.26M
31.4%N/AN/A
73.25M
23.5%20.6%36.9%
80.56M
11.4%11.7%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
76.00M
14.1%58.2%65.4%
145.07M
3.2%3.5%N/A
59.60M
11.8%7.5%N/A
138.52M
1.1%0.8%N/A
54.68M
1.8%N/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.14